Inflammatory modulation of PPARγ expression and activity

被引:17
作者
Crosby, MB
Zhang, J
Nowling, TM
Svenson, JL
Nicol, CJ
Gonzalez, FJ
Gilkeson, GS
机构
[1] Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA
[3] NCI, Lab Metab, NIH, Bethesda, MD 20892 USA
[4] VAMC, Med Res Serv, Charleston, SC 29425 USA
关键词
lupus; nitric oxide; inflammation; PPAR; iNOS; MRL/lpr;
D O I
10.1016/j.clim.2005.09.018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Nitric oxide (NO) production increases with age in the lupus-prone MRL/Ipr mouse, paralleling disease activity. One mechanism for excess NO production in MPL/lpr mice may be a defect in down-regulatory mechanisms of the iNOS pathway. A potential modulator of NO is the nuclear hormone receptor peroxisome proliferation activated receptor gamma (PPAR gamma). We demonstrate that renal PPAR gamma protein expression was altered as disease progressed in MRL/Ipr mice, which paralleled increased iNOS protein expression. Additionally, MRL/lpr-derived primary mesangial cells expressed less PPAR gamma than BALB/c mesangial cells and produced more NO in response to LPS and IFN gamma. Furthermore, PPAR gamma activity was reduced in mesangial cells following exposure to inflammatory mediators. This activity was restored with the addition of a NOS enzyme inhibitor. These results indicate that the activation of inflammatory pathways may lead to reduced activity and expression of PPAR gamma, further exacerbating the disease state. Published by Elsevier Inc.
引用
收藏
页码:276 / 283
页数:8
相关论文
共 45 条
[1]   Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site [J].
Adams, M ;
Reginato, MJ ;
Shao, DL ;
Lazar, MA ;
Chatterjee, VK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (08) :5128-5132
[2]   Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux [J].
Akiyama, TE ;
Sakai, S ;
Lambert, G ;
Nicol, CJ ;
Matsusue, K ;
Pimprale, S ;
Lee, YH ;
Ricote, M ;
Glass, CK ;
Brewer, HB ;
Gonzalez, FJ .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (08) :2607-2619
[3]   Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus [J].
Belmont, HM ;
Levartovsky, D ;
Goel, A ;
Amin, A ;
Giorno, R ;
Rediske, J ;
Skovron, ML ;
Abramson, SB .
ARTHRITIS AND RHEUMATISM, 1997, 40 (10) :1810-1816
[4]   Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat [J].
Braissant, O ;
Foufelle, F ;
Scotto, C ;
Dauca, M ;
Wahli, W .
ENDOCRINOLOGY, 1996, 137 (01) :354-366
[5]  
Camp HS, 1997, J BIOL CHEM, V272, P10811
[6]   N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists.: 3.: Structure-activity relationship and optimization of the N-aryl substituent [J].
Cobb, JE ;
Blanchard, SG ;
Boswell, EG ;
Brown, KK ;
Charifson, PS ;
Cooper, JP ;
Collins, JL ;
Dezube, M ;
Henke, BR ;
Hull-Ryde, EA ;
Lake, DH ;
Lenhard, JM ;
Oliver, W ;
Oplinger, J ;
Pentti, M ;
Parks, DJ ;
Plunket, KD ;
Tong, WQ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (25) :5055-5069
[7]  
Contreras G, 2002, CLIN NEPHROL, V57, P95
[8]  
Culver DA, 2004, AM J RESP CELL MOL, V30, P1
[9]   Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitis [J].
Dubuquoy, L ;
Jansson, EÅ ;
Deeb, S ;
Rakotobe, S ;
Karoui, M ;
Colombel, JF ;
Auwerx, J ;
Pettersson, S ;
Desreumaux, P .
GASTROENTEROLOGY, 2003, 124 (05) :1265-1276
[10]   Troglitazone improves psoriasis and normalizes models of proliferative skin disease -: Ligands for peroxisome proliferator-activated receptor-γ inhibit keratinocyte proliferation [J].
Ellis, CN ;
Varani, J ;
Fisher, GJ ;
Zeigler, ME ;
Pershadsingh, HA ;
Benson, SC ;
Chi, YQ ;
Kurtz, TW .
ARCHIVES OF DERMATOLOGY, 2000, 136 (05) :609-616